Diabetes Mellitus, Non-Insulin-Dependent Clinical Trial
Official title:
A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes.
Administration of the incretin hormone, Glucagon-Like-Peptide-1 (GLP-1), has been shown to enhance insulin secretion and suppress glucagon secretion in response to meal ingestion. In addition, GLP-1 also delays gastric emptying and has been shown to enhance gastric accommodation. These characteristics make GLP-1 an ideal therapy for type 2 diabetes (T2D). However, because of its rapid breakdown by dipeptidylpeptidase IV (DPP IV), GLP-1 has to be administered by continuous intravenous infusion. This would be a drawback in clinical usage. LAF237 is a synthetic inhibitor of DPP IV which has been shown to raise GLP-1 levels and potentiate meal-induced insulin secretion and glucagon suppression. However, the effects of LAF237 on gastric emptying and satiety are at present unknown. The investigators propose to study the effects of LAF237 on gastric emptying, gastric volume and satiety in patients with T2D in addition to examining the direct and indirect (mediated via insulin and glucagon) of this compound on postprandial glucose metabolism.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02801448 -
Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes
|
Phase 2 | |
| Withdrawn |
NCT01377961 -
Effect of Lycopene and Isoflavones on Glucose Metabolism
|
N/A | |
| Completed |
NCT00754130 -
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).
|
Phase 1 | |
| Completed |
NCT00006305 -
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT00004983 -
Education and Group Support for Diabetic Hispanics
|
N/A | |
| Completed |
NCT00010751 -
Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors
|
Phase 2 | |
| Completed |
NCT02299388 -
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
|
Phase 4 | |
| Completed |
NCT00550329 -
Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets
|
Phase 1 | |
| Completed |
NCT00172536 -
Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft
|
N/A | |
| Completed |
NCT00071422 -
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
|
Phase 2 | |
| Completed |
NCT00029848 -
Obese Patients With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT01608724 -
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT01694758 -
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA
|
N/A | |
| Completed |
NCT00979368 -
Safety Study of BMS-816336 in Healthy Male Subjects
|
Phase 1 | |
| Completed |
NCT00791661 -
MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)
|
Phase 1 | |
| Active, not recruiting |
NCT02088658 -
Technology Intensified Diabetes Education Study in African Americans
|
N/A | |
| Completed |
NCT01105429 -
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
|
Phase 1 | |
| Completed |
NCT00701090 -
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00035984 -
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT00044447 -
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
|
Phase 3 |